SC2: Understanding and Modulating Tumor Microenvironment for Immunotherapy

MONDAY, SEPTEMBER 23 | 3:30 – 6:00 PM

Instructors:

RJ Tesi, MD, CEO, CMO, INmune Bio

Mark Lowdell, PhD, Director, Centre for Cell, Gene & Tissue Therapeutics, RFH; Professor, Cell & Tissue Therapy, University College London

This interactive short course tackles our emerging understanding of the role of the tumor microenvironment (TME) in tumor immunotherapy. The TME can have a marked immunosuppressive effect leading to suboptimal responses of tumors to immunotherapies. Strategies to change the immunosuppressive nature of the TME to one that supports immune responses and enhances the impact of tumor immunotherapy will be discussed.

What you will learn:

  • Role of the TME in immune suppression
  • Check point inhibitor optimization
  • Targeting of regulatory cells
  • Reprogramming of immunosuppressive cells
  • Modulation of chemokines and cytokines in the TME
  • Modification of tumor-reactive lymphocytes to evade the TME

Meet the Instructors:

Tesi_RJRJ Tesi, MD, CEO, CMO, INmune Bio

Dr. Tesi is President, Chief Executive Officer and acting Chief Medical Officer since the formation of the Company in September 2015. From November 2011 to May 2015, Dr. Tesi was CEO, President and Acting Chief Medical Officer of FPRT Bio Inc., a development-stage biotech company formed to develop XPro1595 for the treatment of neurodegenerative disease and other inflammatory diseases. From November 2010 to October 2011, Dr. Tesi was Chief Medical Officer of Adienne SRL, an emerging biotech company in Bergamo, Italy focused on products to treat patients with hematologic malignancy. From June 2007 to September 2010, Dr. Tesi was CEO and President of Coronado Biosciences, a company he founded. Dr. Tesi received his MD degree from Washington University School of Medicine in 1982. Dr. Tesi has been a licensed physician since 1982, an academic transplant surgeon and Fellow of the American College of Surgery before transitioning to industry in 1997.

Lowdell_MarkMark Lowdell, PhD, Director, Centre for Cell, Gene & Tissue Therapeutics, RFH; Professor, Cell & Tissue Therapy, University College London

Mark Lowdell, Ph.D has been Co-founder and Chief Scientific Officer since the formation of INmuneBIO in September 2015. The company is an immunotherapy company developing treatments to reprogram the innate immune system to fight disease. Lowdell is also professor of Cell and Tissue Therapy at University College London, where he has led a translational immunotherapy group since 1994. Since February 2009, he has also been Director of Cellular Therapy at the Royal Free London NHS Foundation Trust. Professor Lowdell received his Ph.D in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Japan-Flag   Korea-Flag   China-Simplified-Flag   China-Traditional-Flag